PrIME Biologics has developed a disposable therapeutic plasma manufacturing process intended to increase product yields and enhance safety by removing viruses, bacteria, endotoxins and prions. The company plans to use newly raised capital to establish a human blood plasma fractionation plant in its Singapore cGMP facility. That facility is expected to be registered with the Singapore Health Sciences Authority and fully operational in January 2015. The raise reported in the article is equity financing of SGD16M. Leadership includes Dr Hari Nair, the company's Executive Chairman. The company is positioning itself to scale manufacturing capacity for plasma-derived therapeutics in Singapore.

Total raised

$13M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2014